Introduction
============

Macroautophagy (herein autophagy) is a major intracellular process that is critically crucial for maintaining cellular homeostasis. Autophagy has been reported in several organisms from different kingdoms ranging from yeast to humans suggesting that it is an evolutionarily conserved process. This process was first reported by Christian de Duve ([@B10]), when he observed organelles captured within the lysosomes with the help of electron microscopy ([@B9]). This entire phenomenon of cargo capture and ultimately its degradation in the lysosomes is called "autophagic flux\" ([@B28]; [@B54]; [@B4]).

Basal levels of autophagy occur in all cells during nutrient rich conditions and help in housekeeping functions to maintain cellular quality control by clearance of damaged or surplus organelles and misfolded proteins, recycling and providing basic building blocks like amino acids for reuse (Mizushima and [@B28]; [@B48]). However, the levels of autophagy are highly modulated in response to different stimulus, both intracellular and exogenous such as starvation, pathogen invasion, organelle damage and protein aggregation in cytoplasm ([@B68]; [@B31]). Because autophagy is central to maintaining cellular homeostasis, defective autophagy has been attributed to a variety of disease conditions such as cardiovascular diseases, atherosclerosis, certain myopathies, innate and adaptive immune responses, neurodegeneration and cancer ([@B8]; [@B32]).

Dysfunction of autophagy leads to cell death, cancer, neurodegenerative, and other diseases. Therefore, studying the molecular aspects of autophagy is of current research interest for the treatment of various disease conditions. Genetic and pharmacological modulation of autophagy has been shown to be beneficial in many such situations ([@B57]). Modulation of autophagy has been shown to be beneficial in diseases such as diabetes, cancers, neurodegenerative disorders and some infectious diseases ([@B61]; [@B62]). Several studies in the recent years have discovered novel or repurposed drugs for restoring autophagic balance. For instance, Rapamycin, an autophagy inducer and its analogs were used by Ravikumar et al., to abrogate neurodegeneration in a *Drosophila* based model by enhancing the rates of autophagy ([@B55]; [@B59]). In some of these studies, distinct assays have been developed and used for a High Throughput Screening (HTS) to identify small molecules that modulate autophagy (Table [1](#T1){ref-type="table"}). Several autophagy modulators have been discovered in the recent past but very few of them have led to potential candidate drug molecules. Many of these compounds are specific toward different targets in the autophagy pathway. For example, specific screens to identify novel candidate molecules such as ULK1 ([@B56]), ATG4 ([@B23]), class III phosphatidylinositol 3-kinase ([@B13]), and MTOR ([@B5]), have been carried out. In addition, compounds with broad spectrum effects have also been identified as well ([@B60]). The scope for the discovery of new autophagy modulators that can be later taken up to clinical trials is ever increasing. It has been postulated that deeper insights into autophagy through chemical modulation can lead to better understanding of various diseases. In addition, understanding of the mechanism of these molecules may provide deeper mechanistic insights and understanding of the finely regulated process of autophagy. Chemical biology approach to study autophagy can be compared to a genetic screen ([@B73]; [@B69]; [@B14]; [@B70]), where further studies on the hits reveal more about the mechanism of autophagy. For example, just as the identification of a gene and its function, a manner in which a small molecule modulates autophagy can also shed some light regarding the regulation of autophagy ([@B64]; [@B33]). In search of potential candidate drugs that moderate autophagy, identifying small molecule modulators of autophagy is the primary step. Small molecule study will further enhance the understanding of autophagy and related pathways. Thus, having a robust, sensitive assay to monitor autophagic flux that could be performed at a high throughput rate for the purpose of screening modulators of autophagy is of primary importance (Figure [1](#F1){ref-type="fig"}). In this review, we discuss some of the pharmacological strategies undertaken in the recent past to identify novel autophagy modulators (Table [2](#T2){ref-type="table"}).

###### 

Autophagy modulators identified through High Throughput Screening of Chemical compound libraries.

  Compound                                           Autophagy   General/Selective      Mechanism of                                                                                           Reference
  -------------------------------------------------- ----------- ---------------------- ------------------------------------------------------------------------------------------------------ -----------
  ARP101                                             Inducer     General                Induction of autophagosome biogenesis                                                                  [@B19]
  Bay 11                                             Inhibitor   General                Inhibition of autophagosome biogenesis                                                                 [@B41]
  BRD5631                                            Inducer     Aggrephagy/Xenophagy   --                                                                                                     [@B34]
  Carbamazepine                                      Inducer     Xenophagy              By myo-inositol depletion and AMPK activation                                                          [@B63]
  Cardiac glycosides, e.g., Digoxin, Helveticoside   Inducer     General                Inhibition of Na^+^K^+^ATPases leading to increase in Ca^2+^ levels                                    [@B16]
  KU55933 and Gö6976                                 Inhibitor   General                Inhibition of PI3K                                                                                     [@B13]
  Loperamide                                         Inducer     Aggrephagy             Regulation of intracellular Ca^2+^ levels                                                              [@B78]
  P29A03                                             Inducer     General                Increase in Beclin levels                                                                              [@B36]
  P23C07                                             Inhibitor   General                Inhibition of autophagosomes fusion with lysosomes                                                     [@B36]
  Rottlerin                                          Inducer     General                Inhibition of mTOR through TSC2 pathway                                                                [@B2]
  6-Bio                                              Inducer     Aggrephagy             GSK-3 beta inhibitor                                                                                   [@B65]
  Fasudil                                            Inducer     General                --                                                                                                     [@B17]
  Flubendazole                                       Inducer     Xenophagy              Microtubules destabiliser                                                                              [@B6]
  Minoxidil and clonidine                            Inducer     Aggrephagy             Modulation of cAMP levels                                                                              [@B77]
  Niclosamide                                        Inducer     General                Inhibition of mTOR                                                                                     [@B2]
  Perhexiline                                        Inducer     General                Inhibition of mTOR                                                                                     [@B2]
  SEN177                                             Inducer     Aggrephagy             Inhibition of glutaminyl cyclase                                                                       [@B18]
  SMER10, SMER18, SMER28                             Inducer     Aggrephagy             --                                                                                                     [@B61]
  Trifluoperazine                                    Inducer     Aggrephagy/Xenophagy   Increase in FYVE containing vesicles                                                                   [@B78]
  Tamoxifen                                          Inducer     Xenophagy              Estrogen and G protein coupled receptor GPR30 antagonist shown to inhibit intracellular *Toxoplasma*   [@B11]
  Valproic acid                                      Inducer     Xenophagy              By myo-inositol depletion and AMPK activation                                                          [@B63]
  XCT 790                                            Inducer     Aggrephagy/Xenophagy   ERR alpha inhibitor                                                                                    [@B66]
  ZPCK                                               Inhibitor   General                Inhibition of cargo degradation within lysosomes                                                       [@B41]

![Workflow for screening autophagy modulators. **(A)** Growth based screening: growth inhibition can be induced in yeast due to over expression of aggregate proteins or rapamycin treatment. This cytostatic effect exhibited by yeast can be used as a platform to screen compounds that rescue the growth lag through autophagy induction. After compound treatments, analysis of yeast growth curves identifies the compounds that rescued the growth lag. **(B)** Fluorescence/Luminescence based screening: fluorescent or luminescent reporters are tagged to autophagy proteins for transfection in yeast or mammalian model systems. Modulators of autophagy from chemical libraries are obtained by analyzing the fluorescent/luminescent signal intensities or by visualizing the autophagic vesicle formation by microscopy. **(C)** *In silico* screening: structures of autophagy proteins/motifs of interest can be obtained from data sources like Protein Data Bank and can be used as a model system to identify chemical molecules that bind using *in silico* modeling softwares. The selected lead molecules are then verified in biological system to validate its ability to modulate the process.](fcell-06-00160-g001){#F1}

###### 

Summary of HTS assays for compound libraries.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Model             Assay principle                                                                                                  Read out                                                 Compound(s)               Autophagy   Reference
  ----------------- ---------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- ------------------------- ----------- -----------
  Yeast             Rescue of rapamycin induced growth inhibition                                                                    Growth based assay                                       LY-83583                  --          [@B5]

                    Rescue of rapamycin induced growth inhibition                                                                    Growth based assay                                       SMER 10, 18, and 28       Inducer     [@B61]

                    Rescue of rapamycin induced growth inhibition                                                                    Growth based assay                                       SMIRs                     Inhibitor   [@B61]

                    Rescue of SNCA α-synuclein induced growth lag                                                                    Growth based assay                                       6-Bio                     Inducer     [@B65]

                    Degradation of luciferase tagged peroxisomes                                                                     Luminescence                                             Bay11, ZPCK               Inhibitor   [@B41]

  Mammalian cells   Increase in number of autophagosomes (GFP-LC3)                                                                   Fluorescence microscopy                                  ARP101                    Inducer     [@B19]

                    Increase in number of autophagosomes and autolysosomes (mCherry-GFP-LC3)                                         Flow cytometry                                           Cardiac glycosides        Inducer     [@B16]

                    Degradation of autophagy adaptor proteins (GFP-p62, GFP-NBR1)                                                    Flow cytometry                                           Lactacystin               Inhibitor   [@B35]

                    Reduction in intracellular *Mycobacterium tubercluosis*                                                          Fluorescence microscopy                                  Valproic acid             Inducer     [@B63]

                    Increase in autophagosomes and autolysosomes (mCherry-GFP-LC3)                                                   High-content fluorescent microscopy                      Flubendazole              Inducer     [@B6]

                    Degradation of lipid droplets                                                                                    Fluorescence microscopy                                  P23C07                    Inhibitor   [@B36]

                    Ratio of GFP-LC3 (autophagosomes) and cytosolic RFP-LC3ΔG (internal control) using the probe GFP-LC3-RFP-LC3ΔG   High-content fluorescent microscopy and flow cytometry   Deslanoside, Cladribine   Inducer     [@B22]

                    Ratio of GFP-LC3 (autophagosomes) and cytosolic RFP-LC3ΔG (internal control) using the probe GFP-LC3-RFP-LC3ΔG   High-content fluorescent microscopy and flow cytometry   Mebendazole\              Inhibitor   [@B22]
                                                                                                                                                                                              Nelarabine                            

                    Clearance of A30P α-synuclein                                                                                    Fluorescence microscopy                                  Minoxidil and clonidine   Inducer     [@B77]

                    Quantitation of Nuclear LC3                                                                                      High-content fluorescent microscopy                      NSC179818, NSC60785       --          [@B30]

                    Degradation of luciferase tagged adaptor protein (Luc2p-p62 and Luc2p-p62ΔU)                                     Luminescence                                             Temozolomide              Inducer     [@B40]

                    Renilla Luc tagged LC3 turnover                                                                                  Luminescence                                             KU55933 and Gö6976        Inhibitor   [@B13]

                    Comparison of data expression pattern                                                                            *In silico* data mining                                  Fasudil                   Inducer     [@B17]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Conventional Autophagy Assays
=============================

The real time analysis of autophagy in cells tissues principally been performed via qualitative measures. These assays identify autophagosomes or measure the conversion of LC3I to LC3II (Atg8 in yeast) either through western blotting or microscopy ([@B29]). Owing to the conserved nature of autophagy ([@B44]; [@B21]; [@B38]), the use of yeast as a model system to study autophagy is still widely recognized, even after the identification of homologous Atg sequences in mammalian cells. This is primarily because of the ease of handling and the vast array of biochemical and genetic tools available to carry out autophagy studies. Several different techniques to monitor autophagy are well established in yeast ([@B72]). For example, Pho8Δ60 assay provides readout for bulk autophagy ([@B50]). Wild type alkaline phosphatase protein moves from ER (inactive) to vacuole where it gets activated. Deletion of first 60 amino acids from the N-terminal makes the mutated protein cytosolic which is taken up by the autophagosome machinery along with other cytosolic contents and delivered to vacuole for bulk degradation. The action of vacuolar proteases activates the Pho8Δ60, which can act on different substrates to dephosphorylate them. Depending on the substrate being used, the readout could be measured using either photometry or fluorimetry.

Other classical assays in yeast include monitoring the degradation of fluorescent tagged Atg8 (GFP-Atg8), either through microscopy or immunoblotting ([@B26]; [@B67]; [@B39]). Similarly, autophagic degradation of certain different cargoes like PGK1 or radiolabeled long-lived proteins and organelles like peroxisomes (discussed in later sections) and mitochondria can be chased ([@B73]; [@B27]; [@B58]; [@B76]; [@B47]).

Although yeast studies provide a reliable and efficient way to study autophagy, considering the complexity in higher eukaryotes, the results cannot be always extrapolated. Keeping the role of autophagy in different physiological and pathological contexts in mind, several different autophagy assays have been developed in cell culture ([@B71]; [@B52]). Many of these assays rely on the status of LC3B protein, which is a mammalian homolog of yeast Atg8 protein and is involved in biogenesis and maturation of autophagosome ([@B21]; [@B46]; [@B75]; [@B49]). LC3 gets conjugated to phosphatidyl ethanolamine (PE) on the autophagosome membrane and is the sole marker for autophagosomes right from the biogenesis to its degradation. The form of LC3B conjugated to PE is called LC3B II, while the cytosolic, unconjugated form is referred to as LC3B I. This led to development of various LC3 based assays for monitoring the autophagic flux. Other autophagy marker protein widely utilized for the purpose of autophagy assays is p62/SQSTM1, which is an adaptor protein that helps in cargo sequestration ([@B3]). Different fluorescent reporters are tagged to these markers (mRFP/GFP-LC3) to visualize them under the microscope ([@B21]). *In vivo* studies have also been conducted in the past using the fluorescently labeled LC3 marker. Mizushima et al., used a transgenic mice model expressing the GFP-LC3 protein to show that autophagy occurs in all the cell types. The basal levels of autophagy vary in different tissues and starvation stimulus induces autophagy over and above the basal levels in all the tissues ([@B45]). Tandem fluorescent tags on these proteins (mRFP/mCherry-GFP-LC3) provide an added benefit of visualizing different stages of autophagic flux ([@B25]). This reporter is an indicator of conversion of autophagosomes into autolysosomes upon fusion with lysosomes, wherein the autophagosomes emit both mRFP and GFP signals (mRFP^+^ GFP^+^) whereas the autolysosomes emit only mRFP signal (mRFP^+^ GFP^-^) because GFP is acid-labile and is quenched in the acidic environment of the autolysosomes.

The cytoplasmic autophagic flux of proteins is too small to be chased over a time course using an assay ([@B76]). The turnover rate of cytosolic proteins through basal autophagy is less and does not provide a broad window or physiological range to carry out a screen using protein degradation as a measure. In turn, having an inducible cargo that is specifically degraded through autophagy provides a higher working range. The inadaptability of the conventional autophagy assays into a high throughput setting presents a major limitation and hence makes the small molecule screening a very cumbersome process ([@B7]; [@B74]).

High Throughput Assays to Monitor Autophagy
===========================================

Multiple aspects and steps of the autophagy pathway have been exploited to establish several different HTS assay systems both in yeast and mammalian cells. These have also led to identification of potent novel autophagy modulators (Figure [1](#F1){ref-type="fig"}). Studies on these modulators have not only revealed their therapeutic potential but led to better understanding of the autophagy process.

Growth Based Autophagy Assays
-----------------------------

MTOR is a nutrient sensor and hence is central to cells growth. MTOR also is a regulator of the autophagy pathway ([@B51]; [@B37]). Rapamycin, an inhibitor of MTOR, activates autophagy pathway ([@B1]). This understanding has been widely utilized to develop assays to monitor autophagy via MTOR activity. Butcher *et al.*, developed an assay that monitored the growth of yeast cells each harboring a different plasmid from a pool of 3900 overexpression plasmids in the presence of rapamycin, which is an inhibitor of MTOR ([@B5]). Yeast cells when cultured in the presence of rapamycin, undergo growth inhibition, because of block in TOR pathway. From the pool of overexpression plasmids, candidate gene products were identified that suppressed the cytostatic effect of rapamycin and were involved in the TOR pathway. They also characterized the mechanism of LY-83583. LY-83583 is a novel molecule that suppressed the rapamycin-induced growth inhibition and its several candidate targets were also implicated. [@B61], used yeast to identify small molecule enhancers (SMERs) and inhibitors (SMIRs) of rapamycin using the same strategy. From the screening, 21 SMIRs and 12 SMERs were listed that were structurally non-redundant. They identified SMERs that could enhance autophagy independently of MTOR, and these SMERs (SMER 10, 18, and 28) when tested in mouse and Drosophila models decreased the toxicity associated with mutant Huntington protein, also reflecting on the therapeutic potential of these compounds ([@B61]). The HTS utilized a chemical genetic suppressor platform to rescue or elevate the growth inhibitory properties of rapamycin on wild type yeast cells ([@B15]). Therefore, because of the involvement of MTOR pathway in regulating autophagy, a simple screen based on the growth of yeast was able to give therapeutically potent small molecule hits.

A growth-based neurotoxicity assay in yeast was also utilized by Suresh et al., to identify novel autophagy enhancer 6-Bio that ameliorates α-synuclein toxicity. The compound 6-Bio effectively cleared toxic aggregates in an autophagy dependent manner in both yeast as well as mammalian cells. More importantly, the action of the compound was conserved and showed neuroprotection in a pre-clinical mouse model of Parkinson's disease ([@B65]).

Fluorescence Based High Throughput Assays
-----------------------------------------

Fluorescence based microscopy assays are the most commonly used techniques to monitor autophagic flux. Autophagy, being a multistep process involving several molecular players, presents with a number of markers that can be tagged with a fluorescent probe and the autophagy rates can be monitored. Interestingly, this has also been exploited to design several high content-based imaging strategies to screen for novel autophagy modulators (Figure [1](#F1){ref-type="fig"}).

Clearance of toxic poly glutamine aggregates in cell culture was also demonstrated by using autophagy enhancers obtained from an image based HTS of GFP tagged LC3 puncta representing autophagosomes ([@B78]). The number, size and intensity of the autophagosomes were analyzed and quantified using high throughput fluorescence microscopy. GFP-LC3 was used as a probe in an automated microscopy cell-based assay to identify chemical enhancers that rapidly led to an increase in autophagosome content ([@B2]). The same reporter was also used by [@B19], to identify ARP101, that inhibits matrix metalloproteinase-2 (MMP-2) selectively; as an inducer of autophagy- associated cell death in cancer cells. A high content, flow cytometry based screening approach was used to screen Prestwick Chemical Library containing FDA approved drugs by looking at autolysosome formation and degradation and also endolysosomal activities under basal and stimulated autophagy conditions ([@B16]). This study used three different probes to investigate different stages of autophagic flux (GFP-LC3 for autophagosome, mCherry-GFP-LC3 for autophagosome and autolysosome) and endocytic activity (GFP-Rab7). From the screening, cardiac glycosides were validated as potent enhancers of autophagic flux. The same GFP-LC3 probe has also been used by [@B34], to screen 59,541 small molecules prepared by stereoselective diversity-oriented chemical synthesis and identification of enhancers of autophagy.

[@B35], followed the degradation of three fluorescent tagged autophagy markers: GFP-p62, GFP-NBR1, or GFP-LC3 by flow cytometry of live cells after their promoter has been turned off. Relative degradation rates of these three promoters was analyzed under basal autophagy conditions. Through single cell analysis, GFP-LC3B was found to be the most stable protein whereas GFP-NBR1 was the reporter that was most effectively degraded. The degradation of GFP-p62 was observed to show the strongest response to nutrient limitation condition and was reported to be the best reporter out of the three. Chemical screening strategies have also been used to identify novel target processes that activate autophagy ([@B6]). In this study, LC3B puncta in HeLa cells stably expressing mRFP-GFP-LC3B were analyzed using high-content (HC) image analysis of and revealed a novel role of microtubules, which when altered resulted in autophagy induction.

Autophagy dependent degradation of lipid droplets (LDs) was also used for the development of a high content screening platform to discover novel autophagy modulators ([@B36]). In this study, an indolizine-based fluorescent skeleton called Seoul-Fluor (SF) ([@B24]) that stains the hydrophobic LDs was used and its subsequent degradation via autophagy was followed.

Two anticonvulsants were discovered as mTOR independent autophagy enhancers, from a functional cell-based screening of FDA-approved drugs that were further shown to clear intracellular population of *Mycobacterium tuberculosis* ([@B63]). In this screen, a library of 214 compounds was screened for its ability to kill intracellular luminescent strain of *M. bovis* BCG (bacille-Calmette-Guerin, live attenuated strain of *M. bovis*) within macrophages. These hits were further validated both in primary macrophages and autophagy null cells and also for their effect on autophagy in an mTOR independent manner. The probe GFP-LC3-RFP-LC3ΔG developed by [@B22], serves as a cumulative index for autophagy activity. The probe utilizes the protease activity of the ATG4 family of proteins. Upon cleavage of the fusion protein by ATG4, GFP-LC3 gets associated with the autophagosomes and then degraded upon subsequent fusion to lysosomes. RFP-LC3ΔG on the other hand is cytosolic due to the deletion of glycine at the C-terminal of LC3. This probe can be utilized in different settings like high throughput microscopy, flow cytometry and microplate readers and is also amenable to screening small molecule modulators of autophagy by comparing the ratio of GFP/RFP.

A high content screening in HeLa cells using EGFP-LC3 reporter identified several autophagy inhibitors. These compounds were then further analyzed using an array of phenotypic cell-based assays. The screening strategy identified several hitherto unknown target proteins amongst the well defined targets like Vps34 and ULK1 ([@B53]). In a first of a kind, a high content screening using the fluorescent LC3 reporter, a library of 1539 chemical compounds was aimed to identify modulators that affected the nuclear localization of LC3. Potent modulators were identified that may help in the understanding of LC3 nuclear-cytoplasmic localization ([@B30]).

Parkinson's disease associated protein A30P α-synuclein is a substrate for autophagy and has been used to study aggregate clearance by autophagy in the past. One such study used A30P α-synuclein clearance by autophagy as a primary screen to identify novel autophagy enhancers. Using this screen L-type Ca^2+^ channel antagonists, the K^+^~ATP~ channel opener minoxidil, and the G~i~ signaling activator clonidine were identified as autophagy inducers that work independent of MTOR. This important discovery revealed that MTOR is dispensable for autophagy induction. The authors showed that cAMP can modulate autophagy by controlling IP3 activity ([@B77]). As MTOR is central to several other pathways as well, identification of an alternative pathway opened the scope of controlling autophagy independent of MTOR.

Luminescence Based High Throughput Assays
-----------------------------------------

Luciferase being a sensitive reporter protein comes in handy when an assay has to be scaled to a high throughput format (Figure [1](#F1){ref-type="fig"}). Availability of different luciferase variants further helps in the design of an assay according to the needs. These luciferase variants have different degrees of sensitivity (Nanoluc is more sensitive to Firefly luciferase), different sizes and spectra (*Renilla* luciferase is smaller in size to Firefly luciferase) or different properties (Gaussian luciferase is secretory in nature while Renilla luciferase is cytosolic and Firefly luciferase naturally has a peroxisomal targeting signal). Depending on the need of the assay and the process to be studied, an appropriate luciferase variant may be used in the study. A *Gaussian* luciferase reporter based assay that quantitatively measures the autophagy rate by monitoring proteolytic activity of ATG4B, can be done at a large scale and is quantifiable ([@B23]). This luciferase release assay is well suited for upstream signaling events that either increase or decrease the rates of autophagy. A luciferase-based assay that exploited the property of long lived proteins to be solely degraded via autophagy pathway provided a direct relevance of the autophagy modulation in aggregate prone cells. This assay demonstrated autophagic clearance of an expanded polyglutamine *in vitro* and *in vivo* conditions ([@B20]). This assay takes into account the selective degradation of autophagy cargo using a sensitive luciferase-based reporter. Dynamic and sensitive assay could be achieved by following the cargo that is selective for degradation through autophagy. Peroxisomes provide highly inducible cargo with high turnover rates which are specifically degraded through autophagy machinery under starvation conditions ([@B58]). This high turnover of peroxisomes when combined to the sensitivity of luciferase reporter, provides a very sensitive assay to monitor autophagic flux which is also amenable to high throughput setting. Based on this principle, Mishra et al., designed a screening strategy that allows measurement of autophagic cargo (facultative organelle, peroxisomes) clearance rather than ATG8 based changes in autophagosome number. The principle of the assay is based on detection of the levels of firefly and *Renilla* luciferase activities to monitor the flux of selective and general autophagy, respectively, in *S. cerevisiae* ([@B42]). Reporter strains were constructed that expressed Renilla luciferase and firefly luciferase with a peroxisome targeting signal (PTS1) under a fatty acid responsive promoter. These cells when grown in the presence of fatty acid or glycerol containing media, leads to the expression of peroxisomal firefly luciferase and *Renilla* luciferase which is cytosolic. These cells are then subjected to starvation to induce autophagy. Induction of autophagy leads to selective autophagic degradation of peroxisomes (pexophagy) and also non-selective bulk degradation of cytoplasm. The rate of decay in firefly luciferase activity depicts pexophagy whereas *Renilla* levels depict general autophagy. The dual luciferase assay provides the added advantage of monitoring autophagy in real time, is more sensitive and gives kinetic assessment of two different types of autophagy processes simultaneously. Interestingly, the action of the autophagy modulators identified from the screen was conserved across higher eukaryotes ([@B41]). The autophagy inhibitor Bay11 identified from the screen acted at the autophagosome biogenesis step and ZPCK inhibited the degradation of cargo inside the vacuole/lysosome. These inhibitors had a conserved mode of action across yeast, animals and plants.

Luciferase based HTS autophagy assay has been reported for mammalian cells as well. In a study by [@B40], a luciferase variant Luc2p was fused with the wild type p62/SQSTM1 or a deletion version of p62 (p62 lacking the ubiquitin binding domain) and transfected into glioma cells. The lysates from the two populations (wild type and mutant p62) were compared to monitor the autophagic flux. The performance of this probe was reported to be comparable to GFP-LC3-RFP-LC3ΔG probe described earlier in the review ([@B40]).

*In vitro* and *in silico* Assays
---------------------------------

In recent years, many groups have also carried out a target driven autophagy screen using purified proteins and substrates. To identify substrates for ULK1 that might be involved in the process of autophagy, [@B12], screened degenerate peptide libraries to identify a consensus motif for ULK1 mediated phosphorylation. After identifying novel phosphorylation sites, multiple targets for ULK1 were discovered. These substrates were then used to screen for potent inhibitors of ULK1 phosphorylation.

*Renilla* luciferase based turnover of LC3 was used to screen two kinase inhibitor libraries for identifying inhibitors of autophagic flux ([@B13]). This study identified specific and more potent inhibitors of the upstream signaling component; class III phosphatidylinositol 3-kinase. Inhibitors specific to Ulk1 kinase activity, an upstream protein involved in autophagy initiation were obtained from a screen that utilized purified stress-activated Ulk1 and then looked at the phosphorylation of its substrate, Atg13 at Serine 318 position ([@B56]).

[@B17] used the large dataset of drug expression pattern integrated into "drug network" and identified the previously hitherto unknown functions of several well characterized drugs. This is a dataset of expression profiles constructed while comparing the transcriptional responses induced by different small molecules in human cell lines. Through data mining, they identified fasudil as a novel autophagy enhancer taking the help of the same drug network ([@B17]).

Discussion
==========

Although the core autophagy machinery and the proteins involved in disease conditions might be known, but the exact mechanism of action and how the autophagic flux is regulated is not completely understood which leads to many unanswered questions. Understanding and controlling the autophagic flux either through a genetic or pharmacological approach is a highly promising approach and of great scientific interest. Studies with genetic modulations of autophagic flux have been carried out in the past with immense success. Yoshinori Ohsumi, a pioneer in autophagy field was awarded the Nobel Prize in 2016 for his contribution to the study of autophagic flux. However, chemical modulation has an advantage over genetic manipulations that the phenotype could be observed just on the addition of the compound and the action could be reversed on its withdrawal. The method is less laborious, and the putative modulators could be used as leads for pharmacological purposes in certain disease conditions. However, there are limitations associated with the chemical approach because of the bioavailability issues, toxicity and the secondary or off-target effects associated with the chemical compound. Also, tissue specific effects are difficult to monitor.

To identify novel small molecule modulators of autophagy having a robust and sensitive screening system is the primary step. Therefore, HTS assays for autophagy are of utmost importance as they enable us to screen several small molecules in a small space of time with the inclusion of all possible biological and technical replicates. The data obtained from these assays should be amenable for direct comparison between the control and test groups and statistical analysis. Several high throughput assays have been developed in the recent past to identify small molecule modulators of autophagy. But some limitations associated with these assays must be overcome for a highly potent and effective HTS assay system. Many of these assays have issues with sensitivity and range. They do not directly look at the cargo or possess a higher physiological working range to detect smaller changes in autophagic flux. Although these assays are quantitative but may lack in one of the many parameters required to attain an ideal autophagy assay. An ideal assay would incorporate all these properties such as cargo build up, high sensitivity, ease of experimentation, broader physiological range, and live cell readout in a single high throughput format. Dynamic, sensitive and highly effective assay could be achieved by following the cargo that is inducible and selective for degradation through autophagy.
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